Abstract: A drain cassette for a dialysis unit has a fluid channel between venous and arterial connection ports, and a valve may controllably open and close fluid communication between a drain outlet port and the venous connection port or the arterial connection port. A blood circuit assembly and drain cassette may be removable from the dialysis unit, e.g., by hand and without the use of tools. A blood circuit assembly may include a single, unitary member that defines portions of a pair of blood pumps, control valves, channels to accurately position flexible tubing for an occluder, an air trap support, and/or other portions of the assembly. A blood circuit assembly engagement device may assist with retaining a blood circuit assembly on the dialysis unit, and/or with removal of the assembly. An actuator may operate a retainer element and an ejector element that interact with the assembly.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Hemodialysis and similar dialysis systems including a variety of systems and methods that make hemodialysis more efficient, easier, and/or more affordable, and include new fluid circuits for fluid flow in hemodialysis systems and a reciprocating diaphragm pump for pumping fluids. The reciprocating diaphragm pump includes a flexible diaphragm, a first rigid body having a curved pumping chamber wall, a second rigid body having an opposing curved control chamber wall. The diaphragm is interposed between the pumping chamber wall and the control chamber wall to define a pumping chamber and a control chamber. The diaphragm of the pump has a peripheral bead arranged to locate the diaphragm between the first rigid body and the second rigid body and a diaphragm body having a curved, semi-spheroid or domed shape.

Abstract: A pumping cassette including a housing having at least two inlet fluid lines and at least two outlet fluid lines. At least one balancing pod within the housing and in fluid connection with the fluid paths. The balancing pod balances the flow of a first fluid and the flow of a second fluid such that the volume of the first fluid equals the volume of the second fluid. The balancing pod also includes a membrane that forms two balancing chambers. Also included in the cassette is at least two reciprocating pressure displacement membrane pumps. The pumps are within the housing and they pump the fluid from a fluid inlet to a fluid outlet line and pump the second fluid from a fluid inlet to a fluid outlet.

Abstract: Method and apparatuses for reducing bleeding in a hemophilic patient are described herein. Vagus nerve stimulation augments clotting at the site of injury without precipitating systemic thrombosis, and may be applied to reduce traumatic bleeding in hemophilia A subjects. In particular, vagus nerve stimulation may be applied to reduce traumatic bleeding in hemophilia A subjects that have not received a clotting factor.

Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Provided SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies and fragments thereof, which inhibit the interaction between the spike protein RBM and human ACE2, as well as methods of use employing such antibodies and/or fragments.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Apparatuses and methods for reducing or limiting bleeding in an animal by focused ultrasound (FUS) stimulation of the spleen. The apparatuses and methods may be used treat blood disorders such as hemophilia, or to reduce hemorrhage in surgery or due to traumatic injury. The methods may be non-invasively administered to the patient by transcutaneous application of ultrasound energy.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.

Abstract: A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.